Rhumbline Advisers Reduces Stock Position in OraSure Technologies, Inc. $OSUR

Rhumbline Advisers cut its stake in OraSure Technologies, Inc. (NASDAQ:OSUR) by 5.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 108,933 shares of the medical instruments supplier’s stock after selling 5,822 shares during the period. Rhumbline Advisers owned approximately 0.15% of OraSure Technologies worth $367,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in OSUR. Ameriprise Financial Inc. grew its position in shares of OraSure Technologies by 65.1% in the fourth quarter. Ameriprise Financial Inc. now owns 173,989 shares of the medical instruments supplier’s stock valued at $628,000 after purchasing an additional 68,629 shares in the last quarter. Deutsche Bank AG lifted its holdings in OraSure Technologies by 68.5% in the fourth quarter. Deutsche Bank AG now owns 72,672 shares of the medical instruments supplier’s stock valued at $262,000 after acquiring an additional 29,545 shares during the last quarter. ProShare Advisors LLC lifted its holdings in OraSure Technologies by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 20,327 shares of the medical instruments supplier’s stock valued at $73,000 after acquiring an additional 6,689 shares during the last quarter. Two Sigma Investments LP acquired a new position in OraSure Technologies in the fourth quarter valued at approximately $552,000. Finally, Two Sigma Advisers LP lifted its holdings in OraSure Technologies by 36.9% in the fourth quarter. Two Sigma Advisers LP now owns 97,200 shares of the medical instruments supplier’s stock valued at $351,000 after acquiring an additional 26,200 shares during the last quarter. 93.50% of the stock is currently owned by hedge funds and other institutional investors.

OraSure Technologies Stock Performance

OSUR opened at $3.23 on Thursday. OraSure Technologies, Inc. has a one year low of $2.36 and a one year high of $4.60. The stock has a market capitalization of $236.24 million, a PE ratio of -4.82 and a beta of 0.44. The business’s 50 day moving average price is $3.15 and its 200 day moving average price is $3.06.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.